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THE STUDY
The abstract and summary statements do not take into account the subgroup analyses where it is the OROS agent that shows modest improved symptom benefit compared with short acting MPH by parent report. The teacher report finding may be accounted for by the diminished effect of 2nd generation preparation noted in the subgroup analyses.
the methods as described may not take into account basic assumptions of the pooled analyses where all participants are independent of each other, in that cross over trials have the same individuals in both groups whereas parallel RCTs do not. not clear if the methods account for these differences.
GENERAL COMMENTS
The authors have systematically examined an important clinical management question for pediatric ADHD: what, if any, are the differences in efficacy and safety between short acting and long acting methylphenidate (MPH) treatment for ADHD? The questions is especially relevant as the costs for long acting methylphenidate preparations are significantly greater than those for short acting methylphenidate. They have several significant findings: 1) the OROS long acting preparation has a modest improved effect for inattention and overactivity over short acting preparations for parentrated symptoms on inattention and overactivity, 2) the short acting preparation has a modest improved effect over long acting formulations for teacher rated hyperactivity, 3) all preparations have similar adverse effect profiles.
They highlight the following weaknesses in existing literature 1) almost all the studies compared agents over very short periods of time, 2) most studies were funded by industry and 3) no study met the highest standard for risk for bias, due to lack of detailed reporting for randomization procedures, and lack of published protocols. Alternatively, another explanation that could be further investigated is that of doses compared: Is the "best dose" of long acting (for example 2nd generation) compared against the "best dose" of the other agent? Could this be an explanation for why short acting was better than 2nd generation long acting in school settings?
Methods:
The description of the methods do not account for differences between cross-over trials which enroll and measure outcomes from the same participants in both intervention conditions, and parallel RCT trials which enroll different participants in each condition. There is likely to be additional variability within the parallel group trials, not present in the cross-over trials; therefore not all participants from each trial offers the same kind of information into the pooled analysis. This may violate some of the basic assumptions if independent observations underlying the pooling methods and requires further clarification. How have you, or is there a way to adjust for these differences when combining studies into a single pooled analysis? Perhaps subgroup analyses based on trial method, is an option to investigate for potential differences in effect size due to methods.
Discussion:
The authors have brought up some important issues about the longer term care of patients, moving into a discussion of effectiveness as well as efficacy. The authors rightly comment on the important rationale for longer acting preparations being to improve compliance as well as improve effectiveness over time. They note compliance rates as revealed in the included 3 studies, as not clearly different between short acting and long acting preparations. However two of the studies quoted which do not show a difference look at compliance over 7 days. The third longer lasting study does show a difference favoring OROS. Unfortunately, for answering this question, their inclusion criteria narrowed the results that could be drawn upon, and excluded useful observational studies examining factors predicting compliance, including frequency of doses, and preparation of MPH (Gau et al., 2008 J Clin Psychiatry, Gau et al 2006 . These studies examining compliance in observational study support the results of the 8 week study that OROS provides improved compliance for some children over short acting MPH.
Cost, although important, is not the only issue to keep in mind when it comes to choosing agents for treatment in chronic conditions like ADHD. Patient preference is also highly relevant, not only for adherence, but in the case of MPH, where a second dose of short acting medication is required to be provided at school, important issues are the forgetfulness of the child (part of the disorder) and social stigma of being singled out to take medication at school. While these issues may be less significant for younger children, for those in upper primary school and older, these issues can be significant Q: The statistical sections needs to be expanded to reflect who factors that influence the outcome i.e. the demographics were death with? Were year of publication adjusted in the analysis, this is not mentioned in the results section? Given that clinical practice has changed over the years, I don"t think it is appropriate to combine results that are published in 1980 and 2008. If the authors decide to do his they need to use Meta regression to adjust for other factors, like age and year of publications etc Response: Unfortunately, a meta-regression requires a minimum of 8-10 studies in a single metaanalysis. Our analyses do not obtain this level, and thus a meta-regression was not possible.
Q: I would also suggest that the analysis should be done a)-overall and show the forest plot and b)-in subgroups for those in was parallel and cross-over design, before the other subgroup analysis in figure two are shown. Response: Unfortunately, given the limited number of studies included in each of the analyses, we were unable to subgroup by study design.
Q: How appropriate it is it combine first and second generation treatments. Response: As stated previously, we have decided to subgroup our analyses based on long-acting generation formulation.
Q: From the adverse event table 2, the long acting drug has more side effect than the short acting, this is also needs to be adjusted in analysis. I don"t think using RevMan can be used to analyse this meta-analysis, I would suggest to authors to present also a funnel plot and use STATA to do the analysis. Response: We are not certain what adjustment the reviewer is seeking, however, we have added a sentence in our abstract and conclusion regarding this: The long-acting formulations presented with slightly more total reported adverse events (n=578) as compared with the short-acting formulation (n=566). The abstract and summary statements do not take into account the subgroup analyses where it is the OROS agent that shows modest improved symptom benefit compared with short acting MPH by parent report. The teacher report finding may be accounted for by the diminished effect of 2nd generation preparation noted in the subgroup analyses. Response: The abstract was modified to highlight the findings of this subgroup analysis.
Q: the methods as described may not take into account basic assumptions of the pooled analyses where all participants are independent of each other, in that cross over trials have the same individuals in both groups whereas parallel RCTs do not. not clear if the methods account for these differences.
Response: Because we used standardized mean difference as our pooled value, it is incorrect to adjust the standard deviation of cross-over trials. In the SMD, the SD is incorporated into the effect size under the assumption that the unadjusted SDs are similar across studies, with the differences being due to the different units of measurements. Treating the cross-over studies as if they were parallel will give a more reflective pooled value in the case of SMD.
Q: The initial statement about parent report of inattention/hyperactivity is contradicted by figures.
Response: This statement was removed.
Q: The authors also reveal additional findings that could be further emphasized, and explored and their implications discussed. Heterogeneity was high for relative effect of long acting MPH, and the authors provided a subgroup analysis of the three categories of long-acting methylphenidate, with 1st generation showing no significance difference, second generation showing less efficacy (by parent report) and OROS showing greater efficacy ( by parent report ) than short acting MPH. Here is where the modest benefits of OROS MPH by parent report appeared. And this finding is consistent with literature showing that when short acting MPH was traditionally dosed twice daily, parents reported no noticeable change in symptom benefits, whereas teachers noted symptom benefit ( Schachar et al, J Am Acad Ch Adol Psych, 1997). By contrast the trials showing modest improved effect of short acting MPH over long acting by teacher report of hyperactivity are not trials examining OROS MPH, but first or 2nd generation formulations. Therefore the authors may wish to comment further on the distinction of the different kinds of extended release preparations. Certainly they may not all work as well as each other. In fact, is the basic choice to present a contrast between short acting and long acting clinically inaccurate?. This may be one of the most important findings of the review. Response: We have added this text into the abstract. We have also subgrouped all our analyses by 1st, 2nd and OROS generation long-acting formulations.
Q: Alternatively, another explanation that could be further investigated is that of doses compared: Is the "best dose" of long acting (for example 2nd generation) compared against the "best dose" of the other agent? Could this be an explanation for why short acting was better than 2nd generation long acting in school settings?
Response: This is a potential explanation; however, our data is insufficient to support this statement.
Q: The description of the methods do not account for differences between cross-over trials which enroll and measure outcomes from the same participants in both intervention conditions, and parallel RCT trials which enroll different participants in each condition. There is likely to be additional variability within the parallel group trials, not present in the cross-over trials; therefore not all participants from each trial offers the same kind of information into the pooled analysis. This may violate some of the basic assumptions if independent observations underlying the pooling methods and requires further clarification. How have you, or is there a way to adjust for these differences when combining studies into a single pooled analysis? Perhaps subgroup analyses based on trial method, is an option to investigate for potential differences in effect size due to methods. Response: Please see response above re: crossover studies and standardized mean differences.
Q: The authors have brought up some important issues about the longer term care of patients, moving into a discussion of effectiveness as well as efficacy. The authors rightly comment on the important rationale for longer acting preparations being to improve compliance as well as improve effectiveness over time. They note compliance rates as revealed in the included 3 studies, as not clearly different between short acting and long acting preparations. However two of the studies quoted which do not show a difference look at compliance over 7 days. The third longer lasting study does show a difference favoring OROS. Unfortunately, for answering this question, their inclusion criteria narrowed the results that could be drawn upon, and excluded useful observational studies examining factors predicting compliance, including frequency of doses, and preparation of MPH (Gau et al., 2008 J Clin Psychiatry, Gau et al 2006 . These studies examining compliance in observational study support the results of the 8 week study that OROS provides improved compliance for some children over short acting MPH.
Response: Observational studies lack blinding and randomization and are therefore at a high risk of bias in drawing invalid conclusions. As such, their findings needed replication in more rigorous design to be included in this systematic review.
Q: Cost, although important, is not the only issue to keep in mind when it comes to choosing agents for treatment in chronic conditions like ADHD. Patient preference is also highly relevant, not only for adherence, but in the case of MPH, where a second dose of short acting medication is required to be provided at school, important issues are the forgetfulness of the child (part of the disorder) and social stigma of being singled out to take medication at school. While these issues may be less significant for younger children, for those in upper primary school and older, these issues can be significant and often are weighed in the decision by clinician about what agent to recommend. Also important are the global outcome measures, and likely only very recent trials have reported these, precluding pooled analyses.
Response: Please note that in our discussion, we have pointed out that one of the limitations in this review is that we failed to look at indirect outcomes including academic achievement, social functioning and quality of life. We have also added in that patient preference was overlooked. Another sentence about future research was added into the discussion.
Q: As often happens the systematic review can highlight the gaps in research with suggestions for what are the future research needs. However, some may feel that future trials examining this issue of which agent to compare for chronic treatment of ADHD would not have clinical equipoise, not necessarily due to control of core ADHD symptoms, but due to other issues that are also very important in the practice of evidence based medicine, such as global outcomes and patient preferences. Response: Please see comment above.
